Leukemia Research
Volume 29, Issue 2 , Pages 131-134, February 2005

Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case

  • Joseph H. Butterfield

      Affiliations

    • Division of Allergic Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Ayalew Tefferi

      Affiliations

    • Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    • ,
  • Gerald F. Kozuh

      Affiliations

    • Oncology Joint Practice, Wheaton, IL, USA

Received 12 May 2004; accepted 20 May 2004.

Abstract 

Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F2α excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

Keywords:  c-kit mutation, Interferon-alfa, Prostaglandin F2α, Systemic mastocytosis therapy, Tryptase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(04)00217-6

doi:10.1016/j.leukres.2004.05.003

Leukemia Research
Volume 29, Issue 2 , Pages 131-134, February 2005

Article Tools

* Image Usage & Resolution